aon glp-1 study Can reshape the future of employer health benefits? The Unexpected Workplace Benefit of

Eli Lillys oral GLP-1 candidate orforglipron met all primary and secondary endpoints in a Phase 3 study of adults with type 2 diabetes, the

That is precisely the reasoning I wanted to make tangible

Inclusion of weight loss drugs on insurer formularies is a meaningful step towards expanding access

With the rising awareness and usage of Ozempic, a medication

It highlights emerging evidence, safety considerations, and equity challenges that position GLP-1 RAs as a promising public health strategy for this high-risk population.

The current report aims to present an overview of current knowledge on GLP-1 RAs based on pragmatic review of the available clinical evidence